BMS-986497 (ORM-6151)

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Arms / Cohorts

Experimental, Part 1:Dose Escalation: BMS-986497 (Monotherapy)

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental, Part 2, Cohort A:Dose Expansion: BMS-986497 (Combination Therapy)

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental, Part 2, Cohort B:Dose Expansion: BMS-986497 (Triple Combination Therapy)

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.